You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 55 No. 6, June 1998 TABLE OF CONTENTS
  Archives
  •  Online Features
  Original Contribution
 This Article
 •Full text
 •PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on ISI (23)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Genetic Disorders
 •Cognitive Disorders
 •Movement Disorders
 •Alert me on articles by topic

Severity of Cognitive Impairment in Juvenile and Late-Onset Huntington Disease

Estrella Gómez-Tortosa, MD; Antonio del Barrio, PhD; Pedro J. García Ruiz, MD; Rosario Sánchez Pernaute, MD; Javier Benítez, MD; Alicia Barroso, PhD; F. Javier Jiménez, MD; Justo García Yébenes, MD

Arch Neurol. 1998;55:835-843.

Objectives  To compare the severity of cognitive impairment among groups of patients with different age ranges at the onset of Huntington disease (HD) and to evaluate the variable influence of motor and cognitive deficits on functional disability across different ages at the onset of HD.

Design  Cross-sectional multidisciplinary evaluation of patients referred to our institution for care related to a possible diagnosis of HD.

Setting  The Huntington disease program in the Departments of Neurology and Genetics at the Fundación Jiménez Díaz, Madrid, Spain.

Participants  Seventy-one patients with Huntington disease were classified into 3 groups depending on age at onset of motor symptoms: juvenile onset, 25 years of age or younger (group 1, n=15); adult onset, from 26 to 50 years (group 2, n=43); and late onset, 51 years or older (group 3, n=13). Age- and education-matched controls (n=50) were included to compare cognitive performance with patients in groups 1 and 3.

Measures  Cognitive evaluation encompassed a wide neuropsychological battery to assess global cognitive functioning and visuospatial, prefrontal, and memory functions. Clinical data included motor and functional variables measured by using the Unified Huntington's Disease Rating Scale. Genetic analysis determined the number of CAG trinucleotide repeats.

Results  Patients in group 1 scored 2.9 points and patients in group 3 scored 4.2 points below their respective controls on the Mini-Mental State Examination. Patients in groups 1 and 3 were similarly impaired in verbal memory. Visual function was much more impaired in patients in group 3, and prefrontal functions were slightly worse in patients in group 1. Cognitive scores were correlated only with time of evolution for patients in group 2. Functional scores were not significantly different among the 3 groups, but 11 (85%) of the patients in group 3 were in stage I or II vs 10 (67%) of the patients in group 1. Total functional capacity correlated better with the Mini-Mental State Examination score for patients in group 3 and with motor deficits (akinesia) and prefrontal dysfunction for patients in group 1. The mean±SD CAG repeat length decreased from 59.9±12.6 for patients in group 1 to 46.2±3.5 for patients in group 2 and 41.7±2.6 for patients in group 3. Longer CAG repeats in the HD study population correlated with akinetic features but not with cognitive performance.

Conclusions  Despite the much greater genetic defect, cognitive status is slightly better preserved in patients with juvenile-onset HD. Cognitive impairment in patients with juvenile- and late-onset HD differs in the severity of visual and prefrontal deficits. Functional disability in patients with late-onset HD depends more on global cognitive status, while in patients with juvenile-onset HD, it is conditioned more by motor deficits and prefrontal dysfunction.


From the Departments of Neurology (Drs Gómez-Tortosa, del Barrio, García Ruiz, Sánchez Pernaute, and García Yébenes) and Genetics (Drs Benítez and Barroso), and the Research Unit (Dr Jiménez), Fundación Jiménez Díaz, Madrid, Spain. Dr Gómez-Tortosa is now with the Alzheimer's Research Unit, Massachusetts General Hospital, Boston.



THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Juvenile-Onset Huntington Disease: A Matter of Perspective
Biglan and Shoulson
Arch Neurol 2007;64:783-784.
FULL TEXT  

Speech and language delay are early manifestations of juvenile-onset Huntington disease.
Yoon et al.
Neurology 2006;67:1265-1267.
ABSTRACT | FULL TEXT  

Huntington's disease: Clinical correlates of disability and progression
Mahant et al.
Neurology 2003;61:1085-1092.
ABSTRACT | FULL TEXT  

Unusual Early-Onset Huntington's Disease
Vargas et al.
J Child Neurol 2003;18:429-432.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1998 American Medical Association. All Rights Reserved.